189 related articles for article (PubMed ID: 9589457)
1. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Ohtani H
Pathol Int; 1998 Jan; 48(1):1-9. PubMed ID: 9589457
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.
Saito K; Takeha S; Shiba K; Matsuno S; Sorsa T; Nagura H; Ohtani H
Int J Cancer; 2000 Apr; 86(1):24-9. PubMed ID: 10728590
[TBL] [Abstract][Full Text] [Related]
3. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Migita T; Sato E; Saito K; Mizoi T; Shiiba K; Matsuno S; Nagura H; Ohtani H
Int J Cancer; 1999 Feb; 84(1):74-9. PubMed ID: 9988236
[TBL] [Abstract][Full Text] [Related]
4. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Takeha S; Fujiyama Y; Bamba T; Sorsa T; Nagura H; Ohtani H
Jpn J Cancer Res; 1997 Jan; 88(1):72-81. PubMed ID: 9045899
[TBL] [Abstract][Full Text] [Related]
5. Stromal cell expression of components of matrix-degrading protease systems in human cancer.
Hewitt R; Danø K
Enzyme Protein; 1996; 49(1-3):163-73. PubMed ID: 8797004
[TBL] [Abstract][Full Text] [Related]
6. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.
Danø K; Rømer J; Nielsen BS; Bjørn S; Pyke C; Rygaard J; Lund LR
APMIS; 1999 Jan; 107(1):120-7. PubMed ID: 10190288
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiologic significance of host reactions in human cancer tissue: desmoplasia and tumor immunity.
Ohtani H
Tohoku J Exp Med; 1999 Mar; 187(3):193-202. PubMed ID: 10458476
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Pyke C; Kristensen P; Ralfkiaer E; Grøndahl-Hansen J; Eriksen J; Blasi F; Danø K
Am J Pathol; 1991 May; 138(5):1059-67. PubMed ID: 1850957
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Quax PH; de Bart AC; Schalken JA; Verheijen JH
Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
[TBL] [Abstract][Full Text] [Related]
11. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
12. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
13. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study.
Faouzi S; Le Bail B; Neaud V; Boussarie L; Saric J; Bioulac-Sage P; Balabaud C; Rosenbaum J
J Hepatol; 1999 Feb; 30(2):275-84. PubMed ID: 10068108
[TBL] [Abstract][Full Text] [Related]
14. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
15. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
16. Invasion and metastasis in pancreatic cancer.
Ellenrieder V; Adler G; Gress TM
Ann Oncol; 1999; 10 Suppl 4():46-50. PubMed ID: 10436784
[TBL] [Abstract][Full Text] [Related]
17. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer.
DeClerck YA
Eur J Cancer; 2000 Jun; 36(10):1258-68. PubMed ID: 10882864
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression.
DeClerck YA; Laug WE
Enzyme Protein; 1996; 49(1-3):72-84. PubMed ID: 8796998
[TBL] [Abstract][Full Text] [Related]
19. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Xu Y; Hagege J; Doublet JD; Callard P; Sraer JD; Ronne E; Rondeau E
Hum Pathol; 1997 Feb; 28(2):206-13. PubMed ID: 9023404
[TBL] [Abstract][Full Text] [Related]
20. Control of matrix metalloproteinase activity in cancer.
Jones JL; Walker RA
J Pathol; 1997 Dec; 183(4):377-9. PubMed ID: 9496252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
